Interview with Hoon Han, President, Histostem
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Address: Seongnam jungwongu beltway 210 (sangdaewondong) 101
Tel: (031)-732-1555
Web: http://www.seoulcord.co.kr/index1.asp
Histostem is a stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells. Stem cells are the body’s “master” cells because they give rise to all other tissues, organs, and systems in the body. The stemcells’ ability to differentiate, or change, into other types of cells in the body, is a fairly new discovery that holds tremendous promise for treating and curing some of the most common diseases such as heart diseases, cancers, stroke, paralysis, liver cirrhosis, Buerger’s and Alzheimer’s diseases. What’s more, this treatment is not years away. Histostem is already using hematopoietic stemcells taken from UCB to treat blood diseases such as various kinds of leukemia, multiple sclerosis, amyotrophic lateral sclerosis, etc. Histostem also succeeded in extracting non-hematopoietic multipotent stem cells from UCB in their most pure state and perfected in multiplying and cultivating those stemcells. Histostem is the world’s first runner in applying our stem cell therapy to human patients, and currently using our stem cells to treat with great success such illnesses as Buerger’s disease, Type II diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer’s disease, to name a few. Finally, in order to achieve the most effective donor matching of cord blood to patient, our research technicians are busy typing the human leukocyte antigens (HLA) in our biogenetics laboratory.
Stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells.
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
Lee Kyoung-Ryul has served as Chairman of SCL Healthcare Group since 2007. He discusses the diagnostic service providers’ extensive network in Korea as well as their ambitious plans to export…
On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry…
With a wealth of experience in different countries around the world, Christophe Piganiol came to Korea as general manager of Zuellig Pharma in 2010. Today he discusses the importance of…
Brian Wang, CEO of Korean super-generics developer GL PharmTech, discusses Korea’s relative strengths in different stages of R&D, and how this motivated the foundation and evolution of GL PharmTech. What…
Liz Chatwin came to Korea as general manager of AstraZeneca in the fall of 2013, following a period working at the company’s Chinese affiliate for several years. She contrasts the…
Lee Han-Koo, president of Daehwa Pharmaceutical, explains his strategy to corner the transdermal drug delivery system (TDDS) market through innovative patch products as well as a special focus on oral…
James Jun, CEO of KT&G Life Sciences, discusses his company’s new entry into the Korean pharma market and the role that the KT&G brand can play in accelerating its drug…
Korean success story Boryung has a goal to become the number one domestic pharmaceutical company in the coming years. The company’s CEO, Choi Tae-Hong, discusses this strategy and the victory…
Bae Byoung-Jun, director general of the Bureau of Health Industry at Korea’s Ministry of Health and Welfare, outlines the history and structure of the Korean healthcare system and highlights the…
LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth…
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
See our Cookie Privacy Policy Here
